- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04923607
Phase I Clinical Trial of TQC2731 Injection
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of TQC2731 Injection in Healthy Adult Subjects and Patients With Severe Asthma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Xiaojian Zhang, Bachelor
- Phone Number: +86-0371-66295651
- Email: Zhxj0524@sina.com
Study Locations
-
-
Zhengzhou
-
Henan, Zhengzhou, China, 450052
- First Affiliated Hospital of Zhengzhou University
-
Contact:
- Xiaojian Zhang, Bachelor
- Phone Number: +86-0371-66295651
- Email: Zhxj0524@sina.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects:Sign the informed consent form before the trial, fully understand the trial purpose, process and possible adverse reactions.
- Healthy subjects:Aged between 18 and 60 years old, both men and women;
- Healthy subjects:Female ≥45kg, male ≥50kg, body mass index (BMI) is 18-28 kg/m^2 (including the critical value), BMI=weight (kg)/height^2 (m^2);
- Asthma subjects:Aged between 18 and 70 years old, both men and women;
- Asthma subjects:Female ≥45kg, male ≥50kg;
- Asthma subjects:according to the GINA guidelines (GINA 2020), subjects who received middle, or high-dose ICS in asthma control drugs prescribed by the doctor at least 6 months prior to Visit 1;
Exclusion Criteria:
- Healthy subjects: Pregnant and lactating women;
- Healthy subjects:preexisting or existing heart, endocrine, metabolism, kidney, liver, gastrointestinal, skin, infection, blood, nerve, mental diseases or abnormalities, or related chronic or acute diseases, the investigator assesses that it is not appropriate to participate in the trial;
- Healthy subjects:Those whose vital signs, physical examination, laboratory examination, 12-lead electrocardiogram, and chest radiograph during the screening period are abnormal and have clinical significance;
- Healthy subjects:Hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), human immunodeficiency virus antibody (Anti-HIV) and Treponema pallidum antibody (Anti-TP), any of the above positive subjects;
- Healthy subjects:A history of clinically significant infections before and during screening, including upper respiratory tract infection (URTI) and lower respiratory tract infection (LRTI), and requires antibiotic or antiviral treatment;
- Healthy subjects:Those who have undergone surgery within 4 weeks before screening, or plan to undergo surgery during the study period;
- Asthma subjects: Pregnant and lactating women;
- Asthma subjects:Patients with abnormal vital signs, physical examination, 12-lead electrocardiogram results and clinical significance during the screening period;
- Asthma subjects:preexisting or existing heart, endocrine, metabolism, kidney, liver, gastrointestinal, skin, infection, blood, nerve, or mental illness, etc., or related chronic or acute diseases, the investigator's assessment should not participate in the trial; (except for the target disease)
- Asthma subjects:Accompanied by clinically major lung diseases other than asthma (for example, active lung infection, non-asthmatic chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, obesity-related Hypoventilation syndrome, lung cancer, α1 antitrypsin deficiency, and primary ciliary dyskinesia) or accompanied by pulmonary or systemic diseases other than asthma that lead to increased peripheral blood eosinophil counts (for example, allergic Bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, eosinophilia syndrome). COPD with mainly asthma can be included;
- Asthma subjects:Any disease that has not been stabilized by the investigator, including but not limited to unstable cardiovascular, gastrointestinal, liver, kidney, nervous system, musculoskeletal, infectious, endocrine, metabolic, hematology, mental illness or major physical injury , May: affect the safety of the subject during the entire study period, affect the research results or interpretation of the results, and hinder the subject's ability to complete the entire study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQC2731 injection(sc.) in healthy subjects
For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of TQC2731(12mg、105mg、210mg、420mg、630mg) once. For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg TQC2731 . |
TQC2731 injection
|
Placebo Comparator: Matching Placebo(sc.) in healthy subjects
For the single ascending dose (SAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of matching placebo(12mg、105mg、210mg、420mg、630mg) once. For the multiple ascending dose (MAD) portion of the study, healthy subjects received subcutaneous(sc.) injection of 420mg matching placebo(12mg、105mg、210mg、420mg、630mg). |
Matching placebo with no active ingredients
|
Experimental: TQC2731 injection(SAD,iv.)
Healthy subjects received 210mg TQC2731 intravenously (iv.) once.
|
TQC2731 injection
|
Placebo Comparator: Matching Placebo(SAD,iv.)
Healthy subjects received 210mg matching placebo intravenously (iv.) once.
|
Matching placebo with no active ingredients
|
Experimental: TQC2731 injection(sc.) in asthma subjects
For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.)
injection of TQC2731(70mg、210mg、280mg) .
|
TQC2731 injection
|
Placebo Comparator: Matching Placebo(sc.) in asthma subjects
For the multiple ascending dose (MAD) portion of the study, asthma subjects received subcutaneous(sc.)
injection of matching placebo(70mg、210mg、280mg) .
|
Matching placebo with no active ingredients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
(healthy subject)Number of participants with abnormal clinical symptoms
Time Frame: appropriatly up to Day 253
|
appropriatly up to Day 253
|
(healthy subject)Number of participants with abnormal physical examination
Time Frame: appropriatly up to Day 253
|
appropriatly up to Day 253
|
(healthy subject)Number of participants with abnormal vital signs
Time Frame: appropriatly up to Day 253
|
appropriatly up to Day 253
|
(asthma subject)Number of participants with abnormal laboratory examinations
Time Frame: appropriatly up to Day 253
|
appropriatly up to Day 253
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the drug-time curve
Time Frame: up to Day 253
|
up to Day 253
|
Maximum Concentration
Time Frame: up to Day 253
|
up to Day 253
|
Time to maximum concentration following drug administration
Time Frame: up to Day 253
|
up to Day 253
|
Apparent terminal elimination half-life following drug administration
Time Frame: up to Day 253
|
up to Day 253
|
Apparent volume of distribution
Time Frame: up to Day 253
|
up to Day 253
|
Clearance rate
Time Frame: up to Day 253
|
up to Day 253
|
Incidence and titer of anti-drug antibody (ADA)
Time Frame: up to Day 253
|
up to Day 253
|
Changes in forced expiratory volume (FEV1) in the first second before bronchodilator (before BD administration) from baseline
Time Frame: up to Day 253
|
up to Day 253
|
Changes in exhaled nitric oxide FENO (ppb) in the first second before bronchodilator (before BD administration) from baseline
Time Frame: up to Day 253
|
up to Day 253
|
exhaled nitric oxide FENO (ppb), peripheral blood eosinophils, and total serum IgE
Time Frame: up to Day 253
|
up to Day 253
|
Annualized incidence of acute asthma attack (AAER) and degree
Time Frame: up to Day 253
|
up to Day 253
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQC2731-I-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma Severe Persistent Controlled
-
Lu Yuan LeeNational Institute of Allergy and Infectious Diseases (NIAID)WithdrawnPulmonary Atelectasis | Severe Persistent Asthma | Moderate Persistent Asthma | Nodule Solitary PulmonaryUnited States
-
University of PennsylvaniaCentocor, Inc.Withdrawn
-
Wake Forest UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedAsthma | Severe Persistent AsthmaUnited States
-
Arcispedale Santa Maria Nuova-IRCCSUnknownSevere Persistent AsthmaItaly
-
University of ChicagoWithdrawnSevere Persistent Asthma
-
University of AlbertaWithdrawnSevere Persistent AsthmaCanada
-
University of PisaUniversity Of Perugia; National Research Council, Institute of Clinical Physiology... and other collaboratorsNot yet recruitingAsthma | Asthma Severe Persistent UncontrolledItaly
-
Medical Centre LeeuwardenGlaxoSmithKlineCompleted
-
Sally E. Wenzel MDCompletedAsthma | Severe Persistent AsthmaUnited States
-
Rush University Medical CenterGenentech, Inc.CompletedSevere Persistent AsthmaUnited States
Clinical Trials on TQC2731
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Sinusitis | Nasal PolypsChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting